Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

Partner | Cancer Centers | <b>Dana Farber</b>

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The APHINITY trial showed that adding pertuzumab to chemotherapy and trastuzumab (Herceptin) statistically improved disease-free survival, but the difference was small.

Tolaney says that the patients who benefit significantly from pertuzumab are those who have node-positive hormone receptor-negative disease.